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Background: Smoking is a public health problem in Mexico and worldwide; its economic impact on developing
countries has not been well documented. The aim of this study was to assess the direct medical costs
attributable to smoking incurred by lung cancer patients treated at the National Cancer Institute of
Mexico (INCan).
Methods: The study was conducted at INCan in 2009. We carried out a cost of illness (COI) methodology, using
data derived from an expert panel consensus and from medical chart review. A panel of experts developed a
diagnostic-therapeutic guide that combined the hospital patient pathways and the infrastructure, human
resources, technology, and services provided by the medical units at INCan. Cost estimates in Mexican pesos
were adjusted by inflation and converted into US Dollars using the 2013 FIX exchange rate for foreign
transactions (1 USD = 13.06 Mexican pesos).
Results: A 297 incident cases diagnosed with any type of lung cancer were analyzed. According to clinical
stage, the costs per patient were 13,456; 35,648; 106,186; and 144,555 USD, for lung cancer stages I, II, III, and IV
respectively. The weighted average annual cost/patient was and 139,801 USD and the average annual cost/patient
that was attributable to smoking was 92,269 USD. This cost was independent of the clinical stage, with stage IV
representing 96% of the annual cost. The total annual cost of smoking-related lung cancer at INCan was
19,969,781 USD.
Conclusions: The medical care costs of lung cancer attributable to smoking represent a high cost both for INCan
and the Mexican health sector. These costs could be reduced if all provisions established in the Framework
Convention of Tobacco Control of the World Health Organization were implemented in Mexico.
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Smoking is a worldwide primary public health problem. It
has been estimated that approximately 1.2 billion people
smoke worldwide, and half of them will die of diseases
caused by smoking [1]. Currently, close to six million
smoking-related deaths occur per year. It has been calcu-
lated that this number will increase to eight million deaths* Correspondence: lreynales@insp.mx
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unless otherwise stated.by the year 2030, of which 80% will occur in low- and
medium-income countries [2].
The harmful effects of smoking on individual and popu-
lation health, as well as its economic consequences, are
well described in the international bibliography [3-7].
However, its effects on the economy of developing
countries have not been properly documented, creating
a shortage of scientific information for promoting the
correct implementation of the Framework ConventionThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(WHO-FCTC) in Mexico [8].
Lung cancer (LC) is the main cancer-related cause of
death worldwide in both men and women [9-11]. It has
been estimated that in 2013, there will be 228,190 new
LC cases (118,080 in men and 110,110 in women) and a
total of 159,480 deaths due to LC (87,260 in men and
72,220 in women) in the United States [9]. Considering
that up to 85% of these tumors are associated with
smoking, their incidence has increased in a sustained
fashion since 1970. This increase is attributed to the in-
crease in smoking, especially among women [10,12-16].
A total of 9,148 new cases and 8,807 deaths due to LC
were registered in Mexico in 2008 [10].
LC is classified into two large groups: small cell
(SCLC) and non-small cell (NSCLC) lung cancer. The
latter represents close to 90% of total LC cases, of which
more than 95% of cases are diagnosed at advanced stages
in our country [17,18] and have only a 16% 5-year sur-
vival rate [10,15,17-20]. While the research and develop-
ment of new therapeutic schemes improve patient
quality of life and survival, they also cause a dramatic in-
crease in treatment costs [21-24].
The National Cancer Institute of Mexico (INCan, for
its initials in Spanish) works as the reference site for
patients with the most important types of cancer at a
national scale. It is implemented with all the necessary
human and material resources to provide comprehen-
sive and high quality care for cancer patients. The goal
of this study was to assess the direct medical care costs




To estimate the direct health care costs of Lung cancer
at Incan*, we carried out a cost of illness (COI) method-
ology, using incidence approach. During 2009, 297 inci-
dent cases with any type of NSCLC were admitted. The
patient inclusion criteria were as follows: ≥35 years of
age, current/past smokers and non-smokers at the time
of diagnosis, and subject to medical follow-up for at least
one year after diagnosis. All patients were classified as
stage I, II, III, or IV, according to the TNM classifications
of the 6th edition of the American Joint Committee on
Cancer (AJCC) and the Union for International Cancer
Control (UICC) [25].
Experts’ panel consensus
The technique based on the nominal group or expert
panel consensus [26] was used to define the medical and
clinic characteristics of a patient diagnosed with NSCLC,
which are relevant for cost estimations. For that purpose,
a diagnostic-therapeutic guide was defined. This guidecombined the hospital patient pathways and the infra-
structure, human resources, technology, and services pro-
vided at the INCan.
To do so, the following seven events were defined:
1. Outpatient care
2. Operating room care (surgery)
3. Regular (non-critical care) hospitalization




It is noteworthy that although there is a protocol for
smoking cessation in the first and second levels of health-
care including brief advice and psychotherapeutic support;
there is not a specialized and integrated protocol for giving
up smoking cessation of patients with cancer.
Similarly, for each clinical stage, the human and material
resources required were specified in terms of quantity and
frequency. The medical and nursing procedures for the
medical care of each patient were further defined. The
panel of experts established the units of measure, the quan-
tity used, and the duration of the prescribed medication.
Cost estimates
The finance department at the INCan provided cost in-
formation regarding the different medical services, mate-
rials, medications, and human resources, as well as the
current fixed costs of the institution. The cost assess-
ment was conducted from the perspective of the health-
care service provider using the cost of illness (COI)
methodology. To determine the costs, a micro-costing
model was developed, and the total costs of the disease
were incorporated from the unit costs of the services
provided using the bottom-up methodology [27,28].
Cost estimates in Mexican pesos were adjusted by infla-
tion and converted into US Dollars using the 2013 FIX
exchange rate for foreign transactions (1 USD = 13.06
Mexican pesos).
Medical event cost estimates
The unit cost estimates determining the total cost of the
disease were calculated using an accounting model
[29,30]. The accounting model included the annual salary
of the human resources, which included social benefits.
The capital costs (equipment and installation) were depre-
ciated and prorated according to the equivalent annual
cost (EAC) methodology [27,31]. The cost estimates of the
medications and required materials were conducted based
on the INCan’s consolidated. The unit of measure was
hour/activity (hour/consultation, hour/surgery, hour/regu-
lar hospitalization, hour/ICU hospitalization, hour/chemo-
therapy, hour/radiotherapy, and hour/palliative care).
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MECesptnr ¼Medical event cost per patient; according to
the type of disease
RUesptnr ¼ Resource utilization for the medical care of the
event; according to the type of disease
UCesptnr ¼ Unit price or cost per resource unit used for
patient care; according to the type of disease
d = Disease
=Disease severity: Stage I, II, III, and IV
p =Number of patients
t = Type of medical event: outpatient, operating room,
regular hospitalization, ICU hospitalization, chemother-
apy, radiotherapy, or palliative care
n = Number of medical events {Number of events/l = i}
{1, 2,… n2}
= Resources used during medical care
Average cost estimate per case
After estimating the costs of the medical event, the aver-
age annual cost per patient by NSCLC disease stage was
calculated. The average cost per patient according to









MEACest = Medical event average cost
MECesptnr = Medical event cost for one patient,
according to disease severity
= Number of patients {1,2…n1}
= Number of medical events {Number of events/l = i}
{1, 2,… n2}
nest =Number of patients undergoing the event,
according to disease severity
Case-specific cost estimate, according to disease severity
Once the unit cost of the medical event was obtained, the
average annual cost per case was calculated using the fre-
quency of event occurrence reported by the panel ofexperts. The average cost per patient according to the












ACDSes = Average cost, according to disease severity
MECPesptnr =Medical event cost per patient, according
to the stage of the disease
= Patients {1,2,…n1}
t = Type of medical event: outpatient, operating room,
regular hospitalization, ICU hospitalization,
chemotherapy, radiotherapy, or palliative care
= Number of medical events {Number of events/l = i}
{1, 2,… n2}
= Number of patients per event, according to disease
severity
Total cost of disease at the INCan
The total cost was obtained by multiplying the average an-
nual cost per patient by the number of new NSCLC cases
in 2009. These costs were weighted according to the pa-
tient distribution by medical event and disease stage. In
addition, while the study ran between 2009 and 2010,
costs were adjusted for inflation and estimated at USD







TCDe = Total cost of disease
ACDSes = Average cost, according to disease severity
Nes =Number of patients per event, according to dis-
ease severity
Cost of disease attributable to smoking
The Population Attributable Fraction (PAF) represents
the proportion of NSCLC cases that can be attributed
to a causal factor, which in this case is smoking
[32-35]. Reynales-Shigematsu et al [36] previously esti-
mated the smoking-attributable fraction (SAF) for
NSCLC in the Mexican population ages 35 to 65 that
were covered by the Mexican Social Security Institute
(IMSS, for its initials in Spanish). The weighted SAF
value for NSCLC estimated for Mexico was 0.66 (CI
Table 1 NSCLC Total medical events at INCan in 2009
Event No.
Outpatient care 297
Operating room care (surgery) 20
Regular (non-critical care) hospitalization 192
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costs associated with smoking.
Total smoking-attributable NSCLC cost at the INCan
Finally, to calculate the cost associated with smoking,
the NSCLC SAF was multiplied by the total cost of
NSCLC using the following equation:
SDCe ¼ TCDe  SAFe
Where:
SDCe = Smoking-related cost of disease
TCDe = Total cost of disease
SAFe = Smoking-attributable fraction
Results
Out of a total of 297 patients diagnosed with NSCLC,
1.2% of the cases were detected at an early stage (I and
II); 16% had locally advanced disease (stage III); and 82%
presented with metastatic disease (stage IV).
The number of patients undergoing different medical
events is described in Table 1.
The average length of stay for hospitalized patients
with NSCLC was 22 days. The average daily medical
care cost per patient was 3,328 USD (1,580-4,501 USD),
out of which 2,196 USD (1,043-2,971 USD) was attribut-
able to smoking. The total cost of hospitalization repre-
sented only 2% of the total medical care cost (TMCC)
attributable to smoking. Chemotherapy was the most
costly treatment for patients with stage III and IV NSCLC,
with an average annual medical care cost (AAMCC) of
47,768 USD and 83,868 USD, respectively.
The AAMCC per NSCLC patient was 139,801 USD
(13,456-144,555 USD), and the AAMCC per NSCLC pa-
tient attributable to smoking was 92,269 USD (8,881-
95,406 USD), disregarding the clinical stage of the disease.
The patients with stage III and IV NSCLC were the
most costly, reaching an AAMCC of 106,186 USD and
144,555 USD, respectively. However, surgical procedures
and chemotherapy treatment were the most costly for
patients in stages I and II (Table 2).
For patients with stage I disease, surgical treatment
represented 78.7% of the total cost. For stages II and III,
surgical treatment and chemotherapy represented 71.5%
and 65.1% of the total annual cost, respectively. For
stage IV, outpatient consultations and chemotherapy
represented 75.0% of the total costs (Figure 1).
The TMCC for patients with a first-time diagnosis of
NSCLC was 30,257,245 USD, while the TMCC attribut-
able to smoking was 19,969,781 USD (Table 3).
For the same calendar year, stage IV LC due to smoking
was the most costly, representing 63.6% of the TMCC.
An interesting fact is that the medical care costs in
public hospitals, such as the INCan, are split betweenthe patient and the institution. The division is based on
a payment level category assigned to the patient: the pa-
tient’s payments increase proportionally with the treat-
ment costs, thus decreasing the institutional costs.
Despite some patients being classified as level 1, the
patient’s cost percentage is approximately 70%, given
that medication costs (which account for most of the
costs) are not subsidized by the INCan (Figure 2).
Discussion
This study provides the first detailed cost estimate for the
medical care of NSCLC attributable to smoking at an on-
cology center in Mexico. The results of this study show
that the annual costs attributable to smoking are high for
patients with newly diagnosed NSCLC, exceeding 18
million USD (235 million Mexican pesos). The medical
care costs for recently diagnosed LC patients are mainly
due to surgical and chemotherapy treatments.
In Mexico, during 2013, the medical care costs for
NSCLC attributable to smoking, as estimated by the
Social Security Administration of the Mexican Secretariat
of National Defense (SEDENA, for its initials in Spanish),
were 2.1 million USD (28.4 million Mexican pesos, cal-
culated based on an exchange rate of 1 USD = 13.06
Mexican pesos, according to the information provided by
the Bank of Mexico [Banxico] for 2013). That same year,
the Mexican Institute for Social Security and Services for
State Workers (ISSSTE, for its initials in Spanish) esti-
mated the costs associated with NSCLC attributable to
smoking to be 2.8 million USD (36.7 million Mexican
pesos) [37].
The differences in the total treatment costs for NSCLC
in third-level hospitals in Mexico (IMSS, ISSSTE, and
SEDENA), which were calculated using the same cost
estimate methodology, are mainly due to changes in unit
costs and the frequency of use of the different resources.
Direct cost accounting varies with the level of human re-
source specialization, the implementation of diagnostic
and treatment guidelines, and the unit costs of medica-
tion and equipment (e.g., unit costs for stents) at each
institution. Indirect cost accounting varies with the
available hospital infrastructure (e.g., number of beds for
Table 2 Annual average cost according to clinical stage and medical event per NSCLC patient at INCan. 2013
Lung cancer stages +
Event type I II III IV LC
Annual cost average Weighted annual cost average* Minimum Maximum
Outpatient care $1,280.75 $2,948.96 $15,129.26 $24,606.10 $23,623.40 $1,280.78 $24,606.10
Regular (non-critical care)
hospitalization
$1,580.50 $4,501.53 $2,892.15 $3,359.66 $3,328.02 $1,580.39 $4,501.53
Operating room care (surgery) $10,595.24 $10,816.84 $21,328.31 - $11,510.31 $10,595.24 $21,328.31
Intensive Care Unit
(ICU) hospitalization
- $2,723.22 $2,723.22 $2,723.22 $2,723.22
Chemotherapy administration - $14,658.14 $47,768.79 $83,868.53 $81,240.02 $14,658.14 $83,868.53
Radiotherapy treatment - $9,245.79 $17,522.05 $16,902.06 $9,245.79 $17,522.05
Palliative care - $7,099.35 $12,475.91 $12,192.94 $7,099.35 $12,475.91
Case total $13,456.39 $35,648.68 $106,186.76 $144,555.47 $139,801.87 $13,456.39 $144,555.47
The cost was estimated in Mexican pesos 2009 and was adjusted by inflation for 2013 using the official INPC and inflation rate established by
INEGI http://www.inegi.org.mx/sistemas/indiceprecios/CalculadoraInflacion.aspx.
Currency Dec 2013: USA dollar, 1 dollar = 13.06 Mexican pesos. Exchange according to Bank of Mexico (Banxico) information.
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care units) and the high-cost technology used for diag-
nostic and treatment procedures. In addition to the
aforementioned data, it must be taken into consider-
ation that the analysis of every epidemic must include
the disease incidence and prevalence rates, as well as
its etiology and its impact on population health. To-
bacco addiction can be considered the worst-ever epi-
demic for humanity. Thus, the most appropriate way
to approach it is not only by recognizing its health con-
sequences but also by understanding how the tobacco
industry manipulates the most vulnerable groups, al-
tering the image of the disease-causing agent [12,38].Figure 1 Proportional costs of different interventions in lung cancer pIn the last 100 years, lung cancer went from being a
medical rarity to the main cause of death from cancer in
the world. This increase was achieved by the introduc-
tion of smoking into our society during the first half of
the 20th century, when the proportion of male smokers
was as high as 60% [38,39]. According to the National
Addiction Survey of 2011 in Mexico, the prevalence of
smokers in the population (ages 12 to 65) was 21.7%
[16]. This percentage represents a population of 17.3
million Mexican smokers. In 1989, only 25% of smokers
started smoking at age 12, while in 2011, this fraction
had increased to 50%. That same year, 25,383 deaths
due to smoking were registered, of which 5,615 wereatients by clinical stage.
Table 3 Total costs according to NSCLC clinical stage at
INCan. 2013
Stage+ Annual total cost Annual total cost due to tobacco*
LC I $48,617.17 $32,087.28
LC II $80,957.16 $53,431.72
LC III $985,634.28 $650,518.63
LC IV $29,142,036.54 $19,233,744.07
Total $30,257,245.15 $19,969,781.81
The cost was estimated in Mexican pesos 2009 and was adjusted by inflation for
2013 using the official INPC and inflation rate established by
INEGI http://www.inegi.org.mx/sistemas/indiceprecios/CalculadoraInflacion.aspx.
Currency Dec 2013: USA dollar, 1 dollar = 13.06 Mexican pesos.
Exchange according to Bank of Mexico (Banxico) information.
+Structure established by the Lung Cancer experts of the INCan and the
CIE-10 2009.
*Obtained with tobacco attributable fraction of LC, calculated for national
IMSS; 0.66. Reynales et al.
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main etiological factor for the top 10 causes of morbid-
ity and mortality in Mexico [16].
Despite the existing sub-registry, the Mexican National
Institute of Statistics and Geography (INEGI, for its initials
in Spanish) reported that in 2008, there were more than
9,000 LC-related deaths in our country. This number rep-
resents the second most frequent cause of cancer-related
death in males and the third most frequent one in women,
after prostate and breast/uterine cancer, respectively [40].
In contrast to developed countries, such as the United
States (U.S.) or Europe, where 85% of LC is associated
with smoking, only 66% of LC cases in our country were
found to be due to smoking. While there are other risk
factors, such as wood smoke exposure [18,41], second-
hand smoke [18,42], and tuberculosis [43], the role of to-
bacco as a disease-causing agent cannot be overlooked.
If we compare NSCLC to breast and colorectal cancer,
where advances in treatment have doubled the patientFigure 2 Proportion of lung cancer patients in each payment categorsurvival rates [9,10,44,45], the impact of treatment on
the survival of patients with NSCLC is limited. In the
1960s, the 5-year survival rate was 12%, while it is cur-
rently 16% [42]. Furthermore, smoking is not only associ-
ated with LC development but is also strongly linked to
genetic alterations within the lung tumors themselves,
such as K-Ras mutations [46], which turn them into more
aggressive cancers with poor response to treatment [47].
Even if the present study did not take them into ac-
count, in recent years, the use of targeted therapies has
been shown to improve the survival of NSCLC patients
with specific mutations that make them ideal candidates
for said treatments [46,48-52]. However, these medications
are extremely costly and, generally, poorly accessible to
the Mexican population. This problem is particularly ser-
ious in a developing country, such as ours, where the cost
of medications is similar to their cost in developed coun-
tries. For example, the cost of erlotinib 150 mg (an epider-
mal growth factor receptor [EGFR] inhibitor) is 3,100
USD in the U.S. and close to 3,000 USD in Mexico. How-
ever, the minimum daily wage for 2013 in the U.S. is ap-
proximately 9 USD/hour [53], while in our country, it is
0.57 USD/hour [54]. This difference deepens the existing
inequality for the optimal management of LC patients as-
sociated with the cost of these types of therapy.
Worldwide, tobacco control policies have evolved as evi-
dence of the harmful health effects of smoking has arisen.
The objectives of these policies are to keep the non-
smoking population from consuming tobacco while help-
ing active smokers quit this habit. These policies include
information and education about the risks of smoking,
smoking bans in public spaces, blocking smoking adver-
tisements on television, adding warning labels to cigarette
packs, and raising taxes on tobacco producers. These pub-
lic policy measures have decreased smoking in several de-
veloped countries [38,55]. Unfortunately, the opposite has
happened in developing countries, where the number ofy at INCan.
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agers. This increase is mainly due to the tactics employed
by the tobacco industry and the lack of effective public
policies [1,8,56-58].
Finally, in order to address the generalizability of the
study is is important to mention that, in Mexico, health
care is mainly delivered throughout three institutions:
the Mexican Institute for Social Security (IMSS), the In-
stitute for Social Security and Services for Civil Servants
(ISSSTE) and the Health Department (SSA). The IMSS
is responsible for the health care of 40% of the popula-
tion, whereas the ISSSTE attends 35% and the SSA the
remaining 25% of the mexican population. The INCan,
belongs to the health department. However, is note-
worthy that there are significant differences for NSCLC
treatment among those institutions. Also, there are sev-
eral strengths to this study; it is the first cost estimate
study for NSCLC using the COI methodology in a third-
level medical service center in Mexico covering the
population without social security benefits; employing a
more precise methodology for estimating costs, given
that it used the information in the medical records of
patients. This information allowed a greater precision in
the diagnosis and classification of cases, as well as in the
actual frequency of use of different medical resources.
Our study used financial information to estimate the
medical care costs due to smoking at an institutional
and national level.
Our results provide a powerful argument that endorses
and supports public health policies against smoking.
Our cost information is useful and necessary for estimat-
ing the national budget and how it will be utilized. The
health sector needs to invest in the treatment and pre-
vention of NSCLC over the next decades. Lastly, our re-
sults will allow future cost-effectiveness and cost-benefit
studies to be conducted, which will allow assessment of
the economic impact of tobacco control policies in
Mexico over the last 5 years. The medical care costs of
NSCLC attributable to smoking at the INCan are high.
These increased costs should prompt the authorities to
implement strategies and prevention programs following
the better practices recommended by the WHO-FCTC.
The prevention and control of all modifiable risk factors
related to NSCLC (wood smoke, alcohol abuse, and
smoking) will not only benefit morbidity and mortality
rates but will also represent an important reduction in
healthcare costs at a national level.
This study illustrates the high cost of medical care for
a disease that is largely attributable to smoking. A malig-
nant tumor can be prevented in more than 80% of cases.
The medical care costs reported in this study are cata-
strophic for any patient without health insurance. It
should be noted that this analysis took only tangible costs
into account. Indirect costs due to premature death, earlyretirement, and loss of productivity, among other factors,
were not further studied [36,37,59]. In Mexico, it is im-
perative to implement better and more aggressive tobacco
control policies to reduce the number of deaths that are
attributable to smoking.
Conclusion
The medical care costs incurred by patients with lung can-
cer and a smoking history represent a heavy burden for
both the INCan and the Mexican health care system.
Efforts to enforce the provisions established in the Frame-
work Convention of Tobacco Control of the World Health
Organization should be pursued in order to significantly re-
duce these costs.
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